Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely
Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.
